Related Experiment Videos
Reduced expression of dystroglycan in breast and prostate cancer
M D Henry1, M B Cohen, K P Campbell
1Howard Hughes Medical Institute, Department of Physiology and Biophysics, University of Iowa College of Medicine, Iowa City, IA 52242, USA.
Abstract:
Cellular interactions with the extracellular matrix are an important factor in the development and progression of many types of cancer. Dystroglycan is a cell surface receptor for several extracellular matrix proteins and plays a central role in the formation of basement membranes in tissues. Because abnormalities in the structure and function of basement membranes are hallmarks of metastatic disease, we examined the status of dystroglycan expression in prostate and breast tumors. In 15 cases of surgically resected prostate cancer, we noted reduced expression of dystroglycan as judged by intensity of immunohistochemical staining. This reduction was most pronounced in high-grade disease. We found similar results in 6 cases of mammary ductal adenocarcinoma, suggesting that reduced expression of dystroglycan may be a conserved feature of epithelial neoplasia. These data suggest that reduced expression of dystroglycan in prostate and breast cancers may lead to abnormal cell-extracellular matrix interactions and thus contribute to progression to metastatic disease.
Insights
Reduced expression of dystroglycan, a key protein in tissue structure, was observed in prostate and breast cancers. This finding suggests a link between dystroglycan loss and cancer progression, impacting cell-matrix interactions.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Cellular interactions with the extracellular matrix are crucial in cancer development and progression.
- Dystroglycan is a cell surface receptor essential for basement membrane formation.
- Basement membrane abnormalities are characteristic of metastatic disease.
Purpose of the Study:
- To investigate dystroglycan expression in prostate and breast tumors.
- To determine if reduced dystroglycan is associated with cancer grade and type.
Main Methods:
- Immunohistochemical staining was used to assess dystroglycan expression.
- Analysis was performed on 15 surgically resected prostate cancer cases.
- Analysis was also performed on 6 cases of mammary ductal adenocarcinoma.
Main Results:
- Reduced dystroglycan expression was observed in prostate and breast tumors.
- The reduction in dystroglycan was most pronounced in high-grade prostate cancer.
- Similar findings in breast cancer suggest a conserved role in epithelial neoplasia.
Conclusions:
- Reduced dystroglycan expression may be a common feature in epithelial cancers.
- Loss of dystroglycan could disrupt cell-extracellular matrix interactions.
- This disruption may contribute to the progression of metastatic disease.